ACTU
20/04/2026Résumé IA
Eli Lilly to Acquire Kelonia Therapeutics for Up to $7 Billion
Eli Lilly announced Monday it will acquire Kelonia Therapeutics for up to $7 billion, with $3.25 billion paid upfront and remaining payments tied to clinical, regulatory and commercial milestones. The deal gives Lilly access to Kelonia's in vivo CAR-T technology, which reprograms patients' T-cells inside the body to fight cancer, potentially eliminating the need for complex ex-vivo cell engineering. The transaction is expected to close in the second half of 2026.
C
CNBC1 min de lecture